drugset
drugset / Trial / NCT05255484

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

NCT05255484 ↗

Phase 1/2 Terminated 24 enrolled LaNova Medicines Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

A Phase I/II, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination with Pembrolizumab in Advanced Solid Tumors

Timeline

Start
2022-05-26
Primary completion
2023-10-06
Completion
2023-10-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CAFELKIBART Monoclonal antibody — Intravenous
Subject Pembrolizumab Monoclonal antibody — Intravenous

Indications

neoplasm